Jazz Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.About JAZZ
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.
JAZZ Key Statistics
Stock Snapshot
The current Jazz Pharmaceuticals(JAZZ) stock price is $169.98, with a market capitalization of 10.33B. The stock trades at a price-to-earnings (P/E) ratio of -23.24.
As of 2025-11-17, Jazz Pharmaceuticals(JAZZ) stock has fluctuated between $162.60 and $185.00. The current price stands at $169.98, placing the stock +4.5% above today's low and -8.1% off the high.
The Jazz Pharmaceuticals(JAZZ)'s current trading volume is 5.4M, compared to an average daily volume of 925.6K.
During the past year, Jazz Pharmaceuticals(JAZZ) stock moved between $95.49 at its lowest and $185.00 at its peak.
During the past year, Jazz Pharmaceuticals(JAZZ) stock moved between $95.49 at its lowest and $185.00 at its peak.
JAZZ News
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed...
Zymeworks Inc. (NASDAQ:ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga...
Jazz Pharmaceuticals (JAZZ) is up 20.6%, or $29.04 to $170.11. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter invest...
Analyst ratings
95%
of 20 ratingsMore JAZZ News
In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $205.00. Meet Your ETF AI An...
Jazz Pharmaceuticals (JAZZ) stock took off on Monday after the biopharmaceutical company announced results from a Phase 3 clinical trial. This clinical trial fo...
Zymeworks (ZYME) announced positive topline results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera – zanidatamab-hrii – in combination with chemothera...
Jazz Pharmaceuticals (JAZZ) has drawn fresh attention after reporting strong third-quarter earnings, revising its 2025 guidance, and confirming FDA approval for...
Jazz Pharmaceuticals reported third-quarter 2025 earnings in early November, showing year-over-year increases in revenue (US$1.13 billion) and net income (US$25...